MedTrace Logo

Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards

NCT06319300 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-06-23

No results posted yet for this study

Summary

Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence-assisted insulin decision system to adjust insulin doses for blood glucose control, and the other group received clinician-instituted insulin dose adjustments for blood glucose control. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.

Conditions

  • Diabetes Type 2

Interventions

DEVICE

AI-assisted insulin dose adjustment model

We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients

OTHER

doctor's insulin dose adjustment

participants' insulin doses are adjusted by doctors

Sponsors & Collaborators

  • Shanghai Fifth People's Hospital

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2025-09-20
Completion
2025-09-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319300 on ClinicalTrials.gov